Status:
COMPLETED
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Childhood Atypical Teratoid/Rhabdoid Tumor
Childhood Central Nervous System Germ Cell Tumor
Eligibility:
All Genders
Up to 21 years
Phase:
PHASE1
Brief Summary
This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor ...
Detailed Description
PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose of AZD2171 in pediatric patients with recurrent, progressive, or refractory primary CNS tumors. II. Describe the toxicity profile and dose...
Eligibility Criteria
Inclusion
- Histologically confirmed primary CNS tumor
- Histologically benign brain tumors (e.g., low-grade glioma) allowed
- Histological requirement waived for intrinsic brain stem or diffuse optic pathway tumors, but must have clinical and/or radiographic evidence of progression
- Recurrent, progressive, or refractory disease
- Absolute neutrophil count \>= 1,000/mm\^3 (unsupported)
- Platelet count \>= 75,000/mm\^3 (unsupported)
- Creatinine =\< 1.5 times upper limit of normal (ULN) OR glomerular filtration rate \>= 70 mL/min
- Bilirubin =\< 1.5 times ULN
- ALT =\< 2.5 times ULN
- Urine dipstick or urinalysis \< 1+ protein
- Albumin \>= 3 g/dL
- Karnofsky performance status (PS) 60-100% (\> 16 years of age) OR Lansky PS 60-100% (=\< 16 years of age)
- Karnofsky/Lansky PS 70-100% for patients at increased risk for compromised LVEF
- Hemoglobin \>= 8 g/dL (transfusion support allowed)
- No overt renal, hepatic, cardiac, or pulmonary disease
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- QTc prolongation =\< 500 msec
- No other significant ECG abnormality within the past 14 days
- No clinically significant, unrelated, systemic illness, including serious infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that would preclude study participation
- No uncontrolled hypertension
- Defined as systolic and diastolic BP \> 95th percentile for age (ages 1-17)
- Defined as BP \> 140/90 (ages 18 and older)
- No New York Heart Association class III or IV disease and Karnofsky/Lansky PS \< 70
- Class II disease controlled with treatment and increased monitoring is allowed
- Recovered from all prior therapy
- No prior AZD2171
- At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas)
- More than 1 weeks since prior investigational or biologic agents
- If the investigational or biologic agent has a prolonged half-life (\> 48 hours), then these patients must be discussed with the study chair prior to registration
- No concurrent drugs or biologics with proarrhythmic potential
- More than 3 months since last fraction of craniospinal radiotherapy or total-body irradiation
- More than 4 weeks since last fraction of focal irradiation to symptomatic metastatic sites
- At least 6 months since prior allogeneic bone marrow transplantation
- At least 3 months since prior autologous bone marrow or stem cell transplantation
- At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa (2 weeks for pegfilgrastim)
- No other concurrent investigational agents
- Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose for ≥ 1 week before study entry
- No concurrent chemotherapy
- No concurrent routine use of G-CSF, GM-CSF, or epoetin alfa
- Able to swallow tablets
- Any neurologic deficits must be stable for \>= 1 week
- If the investigational or biologic agent has a prolonged half-life (\> 48 hours), then these patients must be discussed with the study chair prior to registration
Exclusion
- No known curative therapy available
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00326664
Start Date
March 1 2006
End Date
July 1 2015
Last Update
March 7 2016
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Medical Center-Mount Zion
San Francisco, California, United States, 94115
2
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010
3
Lurie Children's Hospital-Chicago
Chicago, Illinois, United States, 60611
4
Dana-Farber/Harvard Cancer Center
Boston, Massachusetts, United States, 02115